BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX Sales of Investments

Cash received from selling or redeeming investments.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments dips below year-ago levels

Q2 FY2026 sales of investments of $25.7M fell 56.2% year over year, behind the +61.7% change in trailing-twelve-month sales of investments. Sequentially, it fell 88.4% from the prior quarter. Over 3 fiscal years it compounded at +29.8% a year.

Context

  • Sales of investments amounted to 29.3% of revenue in FY2025, down 41.8 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -56.2% toward the trailing-twelve-month pace of +61.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$25.7M-88.4% QoQ
Last fiscal yearDec 2025
$256.65M-19.9% YoY
LTMJun 2026
$368.93M+61.7% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.2%——
1 year-19.9%——
3-year CAGR+29.8%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
256.65M USD
Year-over-year change
-19.9%
4-year CAGR
+73.7%

Sales of Investments vs competitors

How BCRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +61.7% is the highest of 3, against a peer median of -26.5%.
  • Sales of investments amounts to 39.2% of revenue for BCRX, versus a peer median of 1633.7%.
BCRX Competitors
Sales of Investments for BCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$1.07B USD-26.1%+50.6%1633.7%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$368.93M USD+61.7%+29.8%39.2%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$366.77M USD-26.9%+72.4%—
PHVSPharvaris N.V.LTM Sep 2026€0 EUR———
Peer median (excluding BCRX) —-26.5%+61.5%1633.7%

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
Deferred Income Tax00000
Stock-Based Compensation34.64M44.7M55.62M65.41M85.07M
Change in Working Capital8.12M(58.95M)(32.4M)(87.28M)(56.9M)
Accounts Receivables(20.82M)(21.47M)(6.1M)(22.7M)(36.81M)
Inventory(8.77M)(12.42M)(1.45M)(4.16M)(1.64M)
Accounts Payables39.41M(22.36M)(16.81M)(62.38M)57.8M
Other Working Capital(1.7M)(2.69M)(8.05M)1.96M(76.26M)
Other Non-Cash Items(1.64M)98.07M106.53M57.48M36.46M
Operating Cash Flow(142.16M)(161.85M)(95.14M)(52.02M)329.88M
Capital Expenditures(2.39M)(1.35M)(2.17M)(1.12M)(2.47M)
Acquisitions (Net)0000(6.18M)
Purchases of Investments(10.01M)(244.28M)(514.41M)(266.76M)(262.24M)
Sales of Investments28.2M117.4M385.08M320.48M256.65M
Other Investing Activities0000550K
Investing Cash Flow15.8M(128.24M)(131.5M)52.59M(13.69M)
Debt Repayment293.87M73.07M58.38M(1.7M)(332.77M)
Common Stock Issued50.06M190K342K34K9.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities15.73M14.77M(26.24M)(4.09M)(8.85M)
Financing Cash Flow359.67M88.03M32.49M(5.76M)(332.44M)
Effect of Forex Changes71K566K362K(936K)(87.07M)
Net Change in Cash233.39M(201.5M)(193.79M)(6.12M)(103.32M)
Free Cash Flow(144.54M)(163.2M)(97.31M)(53.14M)327.41M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.